<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0005">
 <label>Table 1</label>
 <caption>
  <p>Convalescent plasma in patients with respiratory infection by Coronavirus (SARS, MERS, and COVID-19).</p>
 </caption>
 <alt-text id="al0010">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Author</th>
    <th>Country</th>
    <th>Study design</th>
    <th>Viral Etiology</th>
    <th>Diagnosis</th>
    <th>Individuals included</th>
    <th>Non-CP treatment</th>
    <th>Previous clinical state CP</th>
    <th>Dose protocol CP</th>
    <th>Intervention</th>
    <th>Outcomes</th>
    <th>Mortality</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Zhang et al. (2020) 
     <xref rid="bib551" ref-type="bibr">[111]</xref>
    </td>
    <td>China</td>
    <td>Case series</td>
    <td>COVID-19</td>
    <td>RT-PCR</td>
    <td>Intervention: 4</td>
    <td>Lopinavir/Ritonavir, Interferon alpha-2b, oseltamivir, Ribavirin</td>
    <td>Clinical deterioration</td>
    <td>Unknown</td>
    <td>200–400 mL in one or two consecutive transfusions. A patient received 2,400 mL divided in eight consecutive transfusions</td>
    <td>Clinical recovery and discharge from hospital</td>
    <td>0% intervention group</td>
   </tr>
   <tr>
    <td>Shen et al. (2020) [
     <xref rid="bb0190" ref-type="bibr">38</xref>]
    </td>
    <td>China</td>
    <td>Case series</td>
    <td>COVID-19</td>
    <td>RT-PCR</td>
    <td>Intervention: 5</td>
    <td>All patients received antiviral management during treatment.</td>
    <td>Clinical deterioration</td>
    <td>CP from the same donor</td>
    <td>CP 200–250 mL two consecutive transfusions CP 200 mL single dose</td>
    <td>Improvement in viral load and increase in antibodies</td>
    <td>0% intervention group</td>
   </tr>
   <tr>
    <td>Duan et al. (2020) [
     <xref rid="bb0195" ref-type="bibr">39</xref>]
    </td>
    <td>China</td>
    <td>Clinical trial</td>
    <td>COVID-19</td>
    <td>RT-PCR</td>
    <td>Intervention: 19</td>
    <td>Ribavirin, Cefoperazone, Levoflaxacin, Methylprednisolone, Interferon, Peramivir, Caspofungin.</td>
    <td>Clinical deterioration</td>
    <td>CP from the same donor</td>
    <td>CP 200 mL single dose</td>
    <td>Viral load improvement and lung imaging</td>
    <td>Reduction of viral load and improvement in lung images</td>
   </tr>
   <tr>
    <td>Ye et al. (2020) [
     <xref rid="bb0185" ref-type="bibr">37</xref>]
    </td>
    <td>China</td>
    <td>Case series</td>
    <td>COVID-19</td>
    <td>RT-PCR</td>
    <td>Intervention: 6</td>
    <td>Not reported</td>
    <td>Clinical deterioration</td>
    <td>Unknown</td>
    <td>CP 200–250 mL two consecutive transfusions</td>
    <td>Reduction of viral load and increase of SARS-CoV-2 IgG and IgM antibodies</td>
    <td>0% intervention group</td>
   </tr>
   <tr>
    <td>Anh et al. (2020) [
     <xref rid="bb0170" ref-type="bibr">34</xref>]
    </td>
    <td>South Korea</td>
    <td>Case report</td>
    <td>COVID-19</td>
    <td>RT-PCR</td>
    <td>Intervention: 2</td>
    <td>Lopinavir/Ritonavir, hydroxychloroquine and empirical antibiotics</td>
    <td>Clinical deterioration</td>
    <td>Unknown</td>
    <td>Unknown</td>
    <td>Reduction of viral load and increase of SARS-CoV-2 IgG and IgM antibodies</td>
    <td>0% intervention group</td>
   </tr>
   <tr>
    <td rowspan="2">Soo 
     <italic>et al</italic> (2004) [
     <xref rid="bb0200" ref-type="bibr">40</xref>]
    </td>
    <td rowspan="2">China</td>
    <td rowspan="2">Retrospective comparison of cases</td>
    <td rowspan="2">SARS-CoV</td>
    <td rowspan="2">CDC Case Definition</td>
    <td rowspan="2">Intervention: 19, control: 21</td>
    <td>Intervention Group: Ribavirin, 3 doses Methylprednisolone (1 ∙ 5 g).</td>
    <td rowspan="2">Clinical deterioration</td>
    <td rowspan="2">Unknown</td>
    <td rowspan="2">CP 200–400 mL days 11 and 42 after the onset of symptoms</td>
    <td rowspan="2">Mortality, length of hospital stay, adverse events</td>
    <td rowspan="2">23% reduction (
     <italic>p</italic> = .03)
    </td>
   </tr>
   <tr>
    <td>Control group: Ribavirin, 4 or more doses of Methylprednisolone (1 ∙ 5 g).</td>
   </tr>
   <tr>
    <td>Cheng 
     <italic>et al</italic> (2005) [
     <xref rid="bb0205" ref-type="bibr">41</xref>]
    </td>
    <td>China</td>
    <td>Case series</td>
    <td>SARS-CoV</td>
    <td>CDC case definition and serology</td>
    <td>Intervention: 80</td>
    <td>Unknown</td>
    <td>Clinical deterioration</td>
    <td>Unknown</td>
    <td>CP 279 mL per day 14</td>
    <td>Mortality, length of hospital stay</td>
    <td>12.5% intervention group</td>
   </tr>
   <tr>
    <td>Nie et al. (2003) [
     <xref rid="bb0025" ref-type="bibr">5</xref>]
    </td>
    <td>China</td>
    <td>Case series</td>
    <td>SARS-CoV</td>
    <td>Unknown</td>
    <td>Intervention: 40</td>
    <td>Unknown</td>
    <td>Unknown</td>
    <td>Unknown</td>
    <td>CP unknown dose</td>
    <td>Mortality</td>
    <td>0% intervention group</td>
   </tr>
   <tr>
    <td>Yeh 
     <italic>et al</italic> (2005) [
     <xref rid="bb0210" ref-type="bibr">42</xref>]
    </td>
    <td>Taiwan</td>
    <td>Case series</td>
    <td>SARS-CoV</td>
    <td>Serology</td>
    <td>Intervention: 3</td>
    <td>Ribavirin, Moxifloxacin, Methylprednisolone</td>
    <td>Clinical deterioration</td>
    <td>Unknown</td>
    <td>CP unknown dose on day 11 of symptom onset</td>
    <td>Mortality, antibodies, viral load, adverse events</td>
    <td>0% intervention group</td>
   </tr>
   <tr>
    <td>Zhou et al. (2003) [
     <xref rid="bb0215" ref-type="bibr">43</xref>]
    </td>
    <td>China</td>
    <td>Case series</td>
    <td>SARS-CoV</td>
    <td>CDC case definition</td>
    <td>Intervention: 1 control: 28</td>
    <td>All patients received Ribavirin, Azithromycin, Levofloxacin, Steroids, Mechanical ventilation.</td>
    <td>Vulnerable or comorbid older adults</td>
    <td>Unknown</td>
    <td>CP 50 mL single dose on day 17 of symptom onset</td>
    <td>Mortality, length of hospital stay</td>
    <td>7% reduction (
     <italic>p</italic> = .93)
    </td>
   </tr>
   <tr>
    <td>Kong (2003) [
     <xref rid="bb0220" ref-type="bibr">44</xref>]
    </td>
    <td>China (Hong Kong)</td>
    <td>Case report</td>
    <td>SARS-CoV</td>
    <td>Clinical Diagnosis</td>
    <td>Intervention: 1</td>
    <td>Antivirals, Steroids, Ventilation</td>
    <td>Clinical deterioration</td>
    <td>CP from the same donor</td>
    <td>CP 250 mL 2 doses day 7 of the onset of symptoms</td>
    <td>Mortality</td>
    <td>0% intervention group</td>
   </tr>
   <tr>
    <td>Wong 
     <italic>et al</italic> (2003) [
     <xref rid="bb0225" ref-type="bibr">45</xref>]
    </td>
    <td>China (Hong Kong)</td>
    <td>Case report</td>
    <td>SARS-CoV</td>
    <td>WHO case definition</td>
    <td>Intervention: 1</td>
    <td>Ribavirin, Oseltamivir, Cefotaxime, Levofloxacin</td>
    <td>Clinical deterioration</td>
    <td>CP from the same donor</td>
    <td>200 mL CP on day 14 of symptom onset</td>
    <td>Mortality</td>
    <td>0% intervention group</td>
   </tr>
   <tr>
    <td>Ko et al. (2018) [
     <xref rid="bb0175" ref-type="bibr">35</xref>]
    </td>
    <td>South Korea</td>
    <td>Case series</td>
    <td>MERS-CoV</td>
    <td>RT-PCR</td>
    <td>Intervention: 3</td>
    <td>Steroids</td>
    <td>Clinical deterioration</td>
    <td>Unknown</td>
    <td>CP unspecified dose</td>
    <td>Antibody titers</td>
    <td>0% intervention group</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>CDC: Centers for disease control and prevention; COVID-19: Coronavirus disease 2019; CP: Convalescent plasma; MERS-CoV: Middle East respiratory syndrome coronavirus; mL: Millilitres; IgM: Immunoglobulin M; IgG: Immunoglobulin G; NA: Not available; RT PCR: Real-time polymerase chain reaction; SARS-CoV: Severe acute respiratory syndrome coronavirus; WHO: World health organization. Taken and modified from [
    <xref rid="bb0100" ref-type="bibr">20</xref>].
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
